Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Putte – page 140

1 957 clinical trials in Putte, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Putte at a glance
1 957
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 957 trials in Putte

Open in trial search

Short-bowel syndrome

Not recruiting

Long-term safety study of apraglutide (weekly injections) in patients with Short Bowel Syndrome

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Apraglutide
  • Sponsor:VectivBio AG

Multiple sclerosis

Not recruiting

Study on Long-Term Safety and Efficacy of Ocrelizumab for Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Plasma cell myeloma+13

Not recruiting

Study on Atezolizumab and Drug Combinations for Advanced Malignancies in Patients from Previous Atezolizumab Trials

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Dry eye+1

Not recruiting

Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ianalumab
  • Sponsor:Novartis Pharma AG

Asthma

Not recruiting

Study on the Long-term Effects of Dupilumab in Preventing Lung Function Decline in Adults with Uncontrolled Moderate to Severe Asthma

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on the Effectiveness and Safety of Avalglucosidase Alfa for Babies with Infantile-Onset Pompe Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Avalglucosidase Alfa
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on Pembrolizumab for Patients with High-Risk Stage III Melanoma After Surgery

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of DYNE-251 safety and effectiveness in patients with Duchenne muscular dystrophy who are candidates for exon 51 skipping treatment

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Fragment Antibody Targeting Human Tfr1 Conjugated To Phosphorodiamidate Morpholino Oligomer
  • Sponsor:Dyne Therapeutics Inc.

Study of Taldefgrobep Alfa for Patients with Spinal Muscular Atrophy on Stable Nusinersen and/or Risdiplam Regimen or with Onasemnogene Abeparvovec-xioi History

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Taldefgrobep Alfa
  • Sponsor:Biohaven Pharmaceuticals Inc.

Study on the Effects of Fordadistrogene Movaparvovec for Patients with Duchenne Muscular Dystrophy

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Eculizumab
  • Sponsor:Pfizer Inc.

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Breast cancer

Not recruiting

Study on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Putte

What the registry says about research in the country

01 Cardiovascular Diseases

Clinical research in Putte includes studies focused on cardiovascular diseases, with attention on atherosclerotic cardiovascular disease and chronic kidney disease. These trials are designed to evaluate whether new treatments can better protect patients from major heart and vascular complications.

  • Focus on reducing major cardiovascular events
  • Studies involving atherosclerotic cardiovascular disease
  • Includes participants with chronic kidney disease

The research aims to improve treatment effectiveness and support better long-term outcomes for people at elevated cardiovascular risk.

02 Nutritional and Metabolic Diseases

Another area of activity covers nutritional and metabolic diseases, especially obesity and overweight. The studies are evaluating new approaches intended to help with body weight reduction and broader weight-related health improvement.

  • Research centered on obesity management
  • Includes people living with overweight
  • Testing a therapy aimed at lowering body weight

This work reflects growing interest in finding more effective options for metabolic health and weight control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.